Idera Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 5.97 million compared to USD 20.55 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.59 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.59 a year ago. For the nine months, net income was USD 102.21 million compared to net loss of USD 35.96 million a year ago. Basic earnings per share from continuing operations was USD 2.1 compared to basic loss per share from continuing operations of USD 1.09 a year ago. Diluted loss per share from continuing operations was USD 0.46 compared to USD 1.09 a year ago.